The Gold Standard Argument: Why Dermatologists Keep Prescribing Finasteride When Newer Drugs Exist
Photo by Photo by Vitaly Gariev on Unsplash on Unsplash
Walk into any dermatology office in the United States today and ask about hair loss, and there is a reasonable chance your physician will hand you a prescription for finasteride before mentioning anything else. This is not inertia or a lack of awareness about newer options. It is a deliberate clinical judgment rooted in decades of evidence, a well-understood safety profile, and a cost structure that makes long-term adherence realistic for the average American patient.
That said, the pharmaceutical landscape for androgenetic alopecia—the medical term for common pattern hair loss—has expanded meaningfully over the past several years. Oral minoxidil, topical peptide serums, and JAK inhibitors have all generated significant buzz, both in clinical literature and in direct-to-consumer marketing. So why does finasteride remain the recommendation most dermatologists reach for first? The answer requires a careful look at what the evidence actually says.
What Finasteride Does That Others Cannot Easily Replicate
Finasteride works by inhibiting Type II 5-alpha reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). DHT is the primary hormonal driver of androgenetic alopecia in men, and finasteride reduces scalp DHT levels by approximately 60 to 70 percent with daily oral dosing. This mechanism directly addresses the root cause of the condition rather than simply stimulating growth through an unrelated pathway.
This distinction matters clinically. Finasteride does not merely encourage hair follicles to produce thicker strands—it interrupts the hormonal process that is miniaturizing those follicles in the first place. After more than 25 years of post-approval use and multiple large-scale randomized controlled trials, the evidence base supporting finasteride's efficacy in men with male pattern baldness is among the most robust in all of dermatology.
How Newer Treatments Compare
Oral Minoxidil
Oral minoxidil, originally approved as an antihypertensive, has gained traction as an off-label hair loss treatment at low doses (0.625 mg to 2.5 mg daily). Several studies have shown meaningful hair density improvements, and some dermatologists prescribe it as an adjunct or alternative when finasteride is not tolerated. However, oral minoxidil carries cardiovascular considerations—including fluid retention and heart rate changes—that require monitoring, particularly in patients with underlying conditions. It also does not address DHT, meaning it treats the symptom rather than the hormonal mechanism. As a standalone therapy, the long-term data remain thinner than what exists for finasteride.
Topical Peptide Serums
Products featuring peptides such as PTD-DBM, GHK-Cu, or biotinoyl tripeptide-1 have attracted consumer interest, partly driven by social media marketing and partly by a genuine desire to avoid systemic medications. While some small studies suggest modest improvements in hair count or thickness, none of these products have completed the kind of large, placebo-controlled trials that finasteride has undergone. The regulatory status of peptide serums as cosmetics rather than drugs also means they are not subject to the same FDA scrutiny. For a consumer seeking evidence-based assurance, the gap in clinical documentation is substantial.
JAK inhibitors, including baricitinib and ritlecitinib, have generated genuine excitement in dermatology—primarily for alopecia areata, an autoimmune form of hair loss that is mechanistically distinct from androgenetic alopecia. The FDA has approved ritlecitinib specifically for alopecia areata in patients 12 and older. Their application to pattern baldness, however, remains largely investigational, and the cost of these medications—often exceeding $1,500 to $2,000 per month before insurance—places them far outside the reach of most patients for long-term use. Dermatologists are appropriately cautious about prescribing immunomodulating agents for a non-life-threatening cosmetic condition when safer, proven options exist.
The Cost-Benefit Reality for US Consumers
In the United States, cost is not an abstract consideration—it directly shapes whether patients stay on treatment long enough to see results. Hair loss therapies require consistent, long-term use to maintain their benefits. A treatment that works brilliantly but costs $200 a month is functionally less effective than one that costs $30 a month if the patient discontinues after six months due to financial strain.
Generic finasteride, widely available through US pharmacies and specialty health platforms, typically costs between $15 and $40 per month depending on the source. That pricing makes it one of the most accessible chronic treatments in all of men's health. Newer branded options frequently carry price tags that are five to fifty times higher, often without a proportional improvement in outcomes for androgenetic alopecia specifically.
Dermatologists are aware of this reality, and responsible prescribers factor adherence probability into their recommendations. A treatment a patient will actually take consistently is almost always the better clinical choice.
Why Dermatologists Are Not Simply Behind the Curve
It would be a mistake to interpret the medical community's continued preference for finasteride as conservatism or unfamiliarity with newer options. Most practicing dermatologists are well aware of oral minoxidil, peptide formulations, and JAK inhibitor research. Their recommendation of finasteride reflects a considered weighing of evidence quality, risk profile, cost, and mechanism—not a failure to keep up.
When a newer treatment demonstrates superior outcomes in a well-designed head-to-head trial and does so at a comparable or lower cost with a manageable safety profile, prescribing patterns will shift. Until that evidence exists for androgenetic alopecia specifically, finasteride occupies its position at the front of the treatment algorithm for good reason.
Making the Right Decision for Your Hair
If you are navigating hair loss treatment options as a US consumer, the most productive step is a conversation with a licensed dermatologist or healthcare provider who can evaluate your specific pattern, stage of loss, and medical history. What works optimally for one individual may not be the best fit for another.
What the evidence consistently supports, however, is that finasteride remains a highly effective, well-tolerated, and financially accessible foundation for most men with androgenetic alopecia. Newer treatments may eventually challenge that position—but for now, the gold standard retains its standing.
